샘플 요청 목록

 카트 문의
시장보고서
상품코드
1777554

세계의 겸상 적혈구 빈혈 검사 및 스크리닝 시장

Sickle Cell Anemia Testing and Screening
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 371 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

겸상 적혈구 빈혈 검사 및 스크리닝 세계 시장은 2030년까지 7억 1,540만 달러에 달할 전망

2024년에 4억 1,300만 달러로 추정되는 겸상 적혈구 빈혈 검사 및 스크리닝 세계 시장은 2030년에는 7억 1,540만 달러에 달하고, 분석 기간인 2024-2030년 CAGR은 9.6%로 성장할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 헤모글로빈은 CAGR 9.2%를 기록하며 분석 기간 종료시에는 3억 3,830만 달러에 달할 것으로 예측됩니다. 고속 액체 크로마토그래피 분야의 성장률은 분석 기간 동안 CAGR 8.1%로 추정됩니다.

미국 시장은 1억 1,250만 달러로 추정, 중국은 CAGR 13.0%로 성장 예측

미국의 겸상 적혈구 빈혈 검사 및 스크리닝 시장은 2024년에 1억 1,250만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 13.0%를 기록하며 2030년에는 1억 4,480만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 6.9%와 8.4%로 예측됩니다. 유럽에서는 독일이 CAGR 약 7.5%로 성장할 것으로 예측됩니다.

세계 겸상 적혈구 빈혈 검사 및 스크리닝 시장 - 주요 동향 및 촉진요인 정리

겸상 적혈구 빈혈 검사가 전 세계 의료계의 우선순위가 되고 있는 이유는 무엇일까? 조기 진단에 대한 수요 증가에 대한 이해

정부와 의료 기관이 조기 발견과 질병 관리를 우선시함에 따라 겸상 적혈구 빈혈 검사 및 선별 검사가 점점 더 중요해지고 있습니다. 겸상 적혈구증(SCD)은 전 세계적으로 수백만 명이 앓고 있는 유전성 혈액 질환으로, 특히 아프리카, 중동, 인도, 아메리카 일부 지역 등 발병률이 높은 지역에서 많이 발견됩니다. 뇌졸중, 장기 손상, 극심한 통증 등의 합병증을 예방하기 위해서는 조기 진단이 매우 중요합니다. 정부와 보건 기관은 조기 개입을 보장하기 위해 신생아 선별검사 프로그램을 강화하여 환자의 예후를 개선하고 의료 비용을 절감하고 있습니다. 또한, 혼전/출산 전 검진 확대에 따라 접근성이 좋고 정확한 검사 솔루션의 필요성이 더욱 커지고 있습니다. 겸상 적혈구증에 대한 인식이 높아짐에 따라 의료 시스템은 조기 발견과 더 나은 치료 계획을 촉진하기 위해 첨단 선별 기술을 통합하고 있습니다.

기술 발전은 겸상 적혈구 검사를 어떻게 개선하고 있는가? 진단 정확도와 접근성 혁신에 대한 탐구

진단 기술의 발전은 겸상 적혈구 빈혈 검사에 혁명을 가져왔고, 보다 정확하고 신속하며 비용 효율적인 스크리닝 방법을 가능하게 했습니다. 헤모글로빈 전기영동, 고성능 액체 크로마토그래피(HPLC)와 같은 전통적인 임상 검사는 현장진단(POC) 검사 장비, 자동 분자 분석, 유전자 스크리닝 기술 등 차세대 진단 도구로 보완되고 있습니다. 또한, CRISPR을 이용한 유전자 편집 연구로 겸상 적혈구증과 관련된 유전자 변이를 규명할 수 있는 가능성을 열어 정밀의료 접근의 길을 열었습니다. 또한, AI를 활용한 진단 플랫폼은 해석의 정확도를 높이고, 위양성 및 위음성을 감소시키고 있습니다. 재택 검진 키트, 지역 밀착형 검진 키트 등 분산형 검사의 선택지가 확대되면서 의료 인프라가 제한된 원격지에서도 쉽게 검사를 받을 수 있게 되었습니다. 검사 기술의 발전에 따라 겸상 적혈구 빈혈 진단은 보다 효율적이고, 저렴하며, 전 세계적으로 쉽게 이용할 수 있게 되었습니다.

겸상 적혈구 검사의 보급을 가로막는 과제는? 시장 장벽과 의료 격차에 대한 대응 방안

검사 기술의 발전에도 불구하고 겸상 적혈구 빈혈 검사의 보급에는 몇 가지 과제가 있습니다. 저소득 지역에서는 의료 인프라가 제한적이기 때문에 진단 도구의 이용이 어려워 적시에 발견하고 치료할 수 있는 기회가 제한되어 있습니다. 또한, 분자-유전학적 스크리닝 방법은 고가의 비용이 소요되기 때문에 경제적 부담도 우려되어 소외계층이 양질의 의료 서비스를 받기 어려운 실정입니다. 또한, 겸상 적혈구증과 검사 옵션에 대한 인식이 부족하여, 특히 개발도상국에서는 진단이 지연되거나 개입이 늦어지고 있습니다. 규제상의 장애물과 지역별로 검사 가이드라인의 일관성이 없는 것은 시장 확대를 더욱 복잡하게 만들고 있으며, 스크리닝 프로그램을 표준화하기 위해 국제적인 협력 체제를 강화할 필요가 있습니다. 이러한 문제를 해결하기 위해서는 의료 인프라에 대한 집중적인 투자, 정책 개혁, 접근성 및 인식 제고를 위한 공중보건 캠페인이 필요합니다.

겸상 적혈구 빈혈 검사 시장의 성장 원동력은? 주요 확장 추세와 헬스케어 분야에서의 노력 확인

겸상 적혈구 빈혈 검사 및 스크리닝 시장의 성장은 정부 지원 스크리닝 프로그램, 분자진단의 발전, 의료 자금의 증가 등 여러 요인에 의해 이루어지고 있습니다. 전국적인 신생아 검진 의무화는 조기 발견 노력의 확대에 중요한 역할을 하고 있으며, 첨단 진단 기술에 대한 투자를 촉진하고 있습니다. 개발도상국의 겸상 적혈구증 유병률 증가로 인해 저렴한 가격의 확장 가능한 스크리닝 솔루션에 대한 수요가 더욱 가속화되고 있습니다. 또한, 전 세계 보건 기관과 비영리 단체는 질병에 대한 인식과 검사 접근성을 높이기 위한 연구와 지역 기반 프로그램에 자금을 지원하고 있습니다. 유전자 검사 서비스 및 CRISPR 기반 혁신의 확대는 겸상 적혈구증 관리에 있어 맞춤형 의료 접근법의 확산과 함께 시장 성장에 기여하고 있습니다. 진단 방법의 발전과 질병 관리를 개선하기 위한 전 세계적인 노력의 증가로 겸상 적혈구 빈혈 검사 시장은 지속적으로 성장하여 전 세계적으로 환자 결과를 개선할 것으로 예상됩니다.

부문

기술(헤모글로빈, 고속 액체 크로마토그래피, POC(Point of Care) 검사, 기타 검사), 연령층(1세 미만, 25-60나이, 기타), 부문 유형(정부 실험실, 민간 실험실, 기업 실험실, PPP)

조사 대상 기업 사례

  • Alpha Laboratories
  • ASI(Analytical Services International)
  • Atlas Medical
  • Beam Therapeutics
  • BioMedomics Inc.
  • Bio-Rad Laboratories, Inc
  • bluebird bio Inc.
  • Bristol-Myers Squibb Company
  • Cigna
  • CRISPR Therapeutics
  • Daktari Diagnostics
  • Emmaus Life Sciences, Inc.
  • Fisher Scientific
  • Functional Fluidics
  • Global Blood Therapeutics, Inc.(Pfizer Inc.)
  • Hemex Health
  • HEMEX HEALTH
  • HemoTypeSC
  • Imara Inc.
  • KovaDx
  • Laboratory Corporation of America Holdings
  • LABS Inc.
  • Mayo Clinic
  • Modus Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Quest Diagnostics
  • Sanofi SA
  • Silver Lake Research Corporation
  • STRECK, INC

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴로 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.05

Global Sickle Cell Anemia Testing and Screening Market to Reach US$715.4 Million by 2030

The global market for Sickle Cell Anemia Testing and Screening estimated at US$413.0 Million in the year 2024, is expected to reach US$715.4 Million by 2030, growing at a CAGR of 9.6% over the analysis period 2024-2030. Hemoglobin, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$338.3 Million by the end of the analysis period. Growth in the High-Performance Liquid Chromatography segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$112.5 Million While China is Forecast to Grow at 13.0% CAGR

The Sickle Cell Anemia Testing and Screening market in the U.S. is estimated at US$112.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$144.8 Million by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.9% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Global Sickle Cell Anemia Testing and Screening Market - Key Trends & Drivers Summarized

Why Is Sickle Cell Anemia Testing Becoming a Global Healthcare Priority? Understanding the Rising Demand for Early Diagnosis

Sickle cell anemia testing and screening have gained increasing importance as governments and healthcare institutions prioritize early detection and disease management. Sickle cell disease (SCD) is a genetic blood disorder that affects millions worldwide, particularly in regions with high prevalence rates, such as Africa, the Middle East, India, and parts of North and South America. Early diagnosis is crucial in preventing complications such as stroke, organ damage, and severe pain crises. Governments and health organizations have ramped up newborn screening programs to ensure early intervention, leading to improved patient outcomes and reduced healthcare costs. Additionally, the expansion of premarital and prenatal screening initiatives has further reinforced the need for accessible and accurate testing solutions. As awareness of sickle cell disease grows, healthcare systems are integrating advanced screening technologies to facilitate early identification and better treatment planning.

How Are Technological Advancements Improving Sickle Cell Testing? Exploring Innovations in Diagnostic Accuracy and Accessibility

Advancements in diagnostic technology have revolutionized sickle cell anemia testing, enabling more precise, rapid, and cost-effective screening methods. Traditional laboratory tests, such as hemoglobin electrophoresis and high-performance liquid chromatography (HPLC), have been complemented by next-generation diagnostic tools, including point-of-care (POC) testing devices, automated molecular assays, and genetic screening techniques. CRISPR-based gene-editing research has also opened possibilities for identifying genetic mutations associated with sickle cell disease, paving the way for precision medicine approaches. Furthermore, AI-powered diagnostic platforms are enhancing interpretation accuracy, reducing false positives and negatives. The expansion of decentralized testing options, including at-home and community-based screening kits, has made testing more accessible in remote areas with limited healthcare infrastructure. As testing technology continues to evolve, sickle cell anemia diagnostics are becoming more efficient, affordable, and globally accessible.

What Challenges Are Hindering the Adoption of Sickle Cell Testing? Addressing Market Barriers and Healthcare Disparities

Despite the advancements in testing technology, several challenges limit the widespread adoption of sickle cell anemia screening. Limited healthcare infrastructure in low-income regions has hindered the availability of diagnostic tools, restricting access to timely detection and treatment. The high costs associated with molecular and genetic screening methods also pose affordability concerns, making it difficult for underprivileged populations to access quality care. Additionally, inadequate awareness about sickle cell disease and testing options has led to underdiagnosis and delayed interventions, particularly in developing nations. Regulatory hurdles and inconsistent testing guidelines across different regions further complicate market expansion, requiring greater international collaboration to standardize screening programs. Addressing these challenges will require targeted investments in healthcare infrastructure, policy reforms, and public health campaigns to increase accessibility and awareness.

What’s Driving the Growth of the Sickle Cell Anemia Testing Market? Identifying Key Expansion Trends and Healthcare Initiatives

The growth in the sickle cell anemia testing and screening market is driven by several factors, including government-backed screening programs, advancements in molecular diagnostics, and increased healthcare funding. National newborn screening mandates have played a crucial role in expanding early detection efforts, prompting investments in advanced diagnostic technologies. The rising prevalence of sickle cell disease in developing countries has further accelerated the demand for affordable and scalable screening solutions. Additionally, global health organizations and non-profit initiatives are funding research and community-based programs to enhance disease awareness and testing accessibility. The expansion of genetic testing services and CRISPR-based innovations has also contributed to market growth, as personalized medicine approaches gain traction in managing sickle cell disease. With ongoing advancements in diagnostics and increasing global efforts to improve disease management, the market for sickle cell anemia testing is expected to witness sustained growth, improving patient outcomes worldwide.

SCOPE OF STUDY:

The report analyzes the Sickle Cell Anemia Testing and Screening market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests, Other Tests); Age Group (Below 1 yr, 25 - 60 yrs, Others); Sector Type (Government Labs, Private Labs, Corporate Labs, PPP)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Alpha Laboratories
  • ASI (Analytical Services International)
  • Atlas Medical
  • Beam Therapeutics
  • BioMedomics Inc.
  • Bio-Rad Laboratories, Inc
  • bluebird bio Inc.
  • Bristol-Myers Squibb Company
  • Cigna
  • CRISPR Therapeutics
  • Daktari Diagnostics
  • Emmaus Life Sciences, Inc.
  • Fisher Scientific
  • Functional Fluidics
  • Global Blood Therapeutics, Inc. (Pfizer Inc.)
  • Hemex Health
  • HEMEX HEALTH
  • HemoTypeSC
  • Imara Inc.
  • KovaDx
  • Laboratory Corporation of America Holdings
  • LABS Inc.
  • Mayo Clinic
  • Modus Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Quest Diagnostics
  • Sanofi SA
  • Silver Lake Research Corporation
  • STRECK, INC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Sickle Cell Anemia Testing and Screening - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Awareness of Hereditary Blood Disorders Throws the Spotlight on Sickle Cell Screening Programs
    • Expansion of Neonatal and Prenatal Genetic Screening Drives Early Diagnosis of Sickle Cell Anemia
    • OEM Innovation in Point-of-Care Diagnostic Devices Enhances Access in Low-Infrastructure Settings
    • Growth in National Health Missions and Public Health Campaigns Spurs Universal Screening Mandates
    • OEM Development of Cost-Effective, High-Accuracy Lateral Flow Assays Supports Rural Deployment
    • Rising Birth Prevalence in Sub-Saharan Africa, India, and Middle East Expands Addressable Market
    • OEM Integration of Multiplex Testing Platforms Improves Detection Accuracy and Workflow Efficiency
    • Regulatory Support for Newborn Screening and Carrier Testing Strengthens Diagnostic Uptake
    • Surge in Gene Therapy Clinical Trials Promotes Pre-Treatment Genotyping and Risk Stratification
    • OEM Collaboration With Blood Banks and Pediatric Hospitals Enhances Institutional Testing Infrastructure
    • Expansion of Community-Based Outreach Models Encourages Voluntary Screening and Genetic Counseling
    • OEM Focus on Mobile Diagnostic Vans and Home Collection Models Expands Reach in Underserved Regions
    • Increasing Use of Telemedicine for Genetic Interpretation and Counseling Supports Screening Continuity
    • OEM Investment in Digital Records and National Screening Registries Enhances Patient Tracking
    • Rising Support From NGOs and Global Health Agencies Drives Free or Subsidized Testing Programs
    • OEM Partnerships With Pharma Companies Enable Companion Diagnostics in Targeted SCD Treatments
    • Growth in Workplace and School-Based Screening Initiatives Supports Preventive Health Policies
    • OEM Innovation in Saliva and Dried Blood Spot Sampling Improves Testing in Infants and Adolescents
    • Shift Toward Carrier Identification and Premarital Screening Programs Promotes Informed Reproductive Choices
    • Focus on Equity, Inclusion, and Stigma Reduction Enhances Public Acceptance of Mass Screening Campaigns
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sickle Cell Anemia Testing and Screening Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hemoglobin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hemoglobin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Hemoglobin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for High-Performance Liquid Chromatography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for High-Performance Liquid Chromatography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for High-Performance Liquid Chromatography by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Point-of-Care Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Point-of-Care Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Point-of-Care Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Corporate Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Corporate Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Corporate Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for PPP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for PPP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for PPP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Government Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Government Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Government Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Private Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Private Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Private Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Below 1 yr by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Below 1 yr by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Below 1 yr by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for 25 - 60 yrs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for 25 - 60 yrs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for 25 - 60 yrs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • JAPAN
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • CHINA
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • EUROPE
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • FRANCE
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • GERMANY
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • INDIA
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030
  • AFRICA
    • Sickle Cell Anemia Testing and Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Sickle Cell Anemia Testing and Screening by Technology - Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Technology - Percentage Breakdown of Value Sales for Hemoglobin, High-Performance Liquid Chromatography, Point-of-Care Tests and Other Tests for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Sickle Cell Anemia Testing and Screening by Sector Type - Corporate Labs, PPP, Government Labs and Private Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Sector Type - Percentage Breakdown of Value Sales for Corporate Labs, PPP, Government Labs and Private Labs for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Sickle Cell Anemia Testing and Screening by Age Group - Below 1 yr, 25 - 60 yrs and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Sickle Cell Anemia Testing and Screening by Age Group - Percentage Breakdown of Value Sales for Below 1 yr, 25 - 60 yrs and Others for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제